Velarion · Company Intelligence
Compensation Brief
Fiscal year 2024 · Filings through 2025-07-03

Inozyme Pharma (INZY)

CEO Douglas Treco was paid $2,485,392 in fiscal year 2024, ↓ down 53.1% from fiscal year 2023 (SEC filing 0000950170-25-060198 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,485,392 ↓
Douglas Treco total, FY2024
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2024

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Douglas Treco$541,667$0$0$1,933,375$0$0$10,350$2,485,392
Chief Executive Officer and Chairman
Matthew Winton456,7500—1,162,799135,000010,3501,764,899
Senior Vice President and Chief Operating Officer
Sanjay Subramanian462,033001,096,354135,000010,3501,703,737
Senior Vice President and Chief Financial Officer and Head of Business Development

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Douglas Treco$2,485,392$5,299,476—↓ −2,814,084
Matthew Winton1,764,8991,548,627—↑ +216,272
Sanjay Subramanian1,703,7371,032,937—↑ +670,800

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Inozyme Pharma's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper INZY reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against INZY
5 companies name INZY as a compensation peer

The list of companies that name INZY as a peer is temporarily unavailable — recheck shortly.

01b

Executives — the named officers

One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.

ExecutiveRoleFY2024 total
Douglas TrecoCEO$2,485,392
Matthew WintonCOO$1,764,899
Sanjay SubramanianCFO$1,703,737
01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2024 total
Axel BolteDirector$164,093
Edward MathersIndependent Director$170,950
Erik HarrisIndependent Director$282,286
Lynne SullivanIndependent Director$176,950
Martin EdwardsIndependent Director$185,450
Reinaldo DiazLead Independent Director$191,325
Robert HopfnerIndependent Director$166,950
Sarah BhagatIndependent Director$171,966
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Axel BolteDirector2025-05-15A152,823$1$149,767CommonForm 4 ↗
Axel BolteDirector2025-05-15D152,82300Derivative, Class A CommonForm 4 ↗
Axel BolteDirector2025-05-15D4,40700Derivative, Class A CommonForm 4 ↗
Axel BolteDirector2025-05-15A4,40714,319CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-06-25A6,81315,042CommonForm 4 ↗
Douglas A. TrecoDirector2025-06-25A2,81512,083CommonForm 4 ↗
Matthew WintonCOO2025-06-25A14,355110,623CommonForm 4 ↗
Robert HopfnerDirector2025-07-01D2,923,110411,692,440CommonForm 4 ↗
Douglas A. TrecoDirector2025-07-01D400,000——Derivative, Class A CommonForm 4 ↗
Axel BolteDirector2025-07-01D423,92641,695,704CommonForm 4 ↗
Matthew WintonCOO2025-07-01D145,000——Derivative, Class A CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-07-01D135,000——Derivative, Class A CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-07-01D38,500——Derivative, Class A CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-07-01D39,7014158,804CommonForm 4 ↗
Robert HopfnerDirector2025-07-01D1,571,74146,286,964CommonForm 4 ↗
Douglas A. TrecoDirector2025-07-01D43,8614175,444CommonForm 4 ↗
Axel BolteDirector2025-07-01D234,176——Derivative, Class A CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-07-01D145,000——Derivative, Class A CommonForm 4 ↗
Douglas A. TrecoDirector2025-07-01D86,979——Derivative, Class A CommonForm 4 ↗
Axel BolteDirector2025-07-01D159,187——Derivative, Class A CommonForm 4 ↗
Matthew WintonCOO2025-07-01D41,500——Derivative, Class A CommonForm 4 ↗
Sanjay SubramanianSVP, CFO & Head of BD2025-07-01D180,000——Derivative, Class A CommonForm 4 ↗
Matthew WintonCOO2025-07-01D21,743486,972CommonForm 4 ↗
Douglas A. TrecoDirector2025-07-01D150,000——Derivative, Class A CommonForm 4 ↗
Lynne SullivanDirector2025-07-01D28,368——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2024

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Matthew WintonRSU—————$1,162,799
Douglas TrecoOption—————1,933,375
Sanjay SubramanianOption—————1,096,354
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Matthew Winton$1,162,799$0$00.0%
Douglas Treco001,933,3750.0%
Sanjay Subramanian001,096,3540.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Douglas TrecoRSU75,000—$207,750
Douglas TrecoOption466,6675.73—
Douglas TrecoOption243,7505.77—
Sanjay SubramanianOption56,2503.96—
Sanjay SubramanianOption75,9383.3—
Sanjay SubramanianOption134,0635.77—
Matthew WintonOption145,8345.39—
Matthew WintonOption142,1885.77—
05

Incentive-plan design — the Compensation Discussion & Analysis

The company's compensation program is designed to motivate executive officers to achieve annual goals based on strategic, financial, and operating performance objectives, while equity grants with time-based vesting features are used to promote retention and align executive interests with stockholders.

CEO STI target (% of salary)55%
CEO LTI target (% of salary)—
Independent consultantAlpine Rewards
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-18—————
20232023-06-13—————
20222022-06-10—————
20212021-06-23—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20242024-06-18—a
20232023-06-13—b
20222022-06-10—c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

08

Director compensation — fiscal year 2024

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Erik HarrisIndependent · Newly elected$9,783$0$272,503—$0$282,286
Reinaldo DiazIndependent · Lead Independent Director · Compensation (Chair)68,1250123,200—0191,325
Martin EdwardsIndependent · Nominating and Corporate Governance (Chair) · Audit · Research and Development (Chair)62,2500123,200—0185,450
Lynne SullivanIndependent · Audit (Chair)53,7500123,200—0176,950
Sarah BhagatIndependent · Audit48,7660123,200—0171,966
Edward MathersIndependent · Compensation · Nominating and Corporate Governance47,7500123,200—0170,950
Robert HopfnerIndependent · Compensation43,7500123,200—0166,950
Axel BolteNot independent · Research and Development40,8930123,200—0164,093
Douglas A. TrecoEmployee director · Board Chair · Research and Development000—00
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)7,500 / 5,000 / 4,000
Stock ownership guideline—
09b

Total cost of the board

ComponentFY2024
Cash retainers and fees$375,067
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$375,067

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Inozyme Pharma2024Douglas Treco$541,667$0$1,933,375$0$2,485,392

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at Inozyme Pharma in fiscal 2024?
As disclosed, Douglas Treco (Chief Executive Officer and Chairman) was the highest-paid executive at Inozyme Pharma in fiscal 2024, with total compensation of $2,485,392.
How much does Inozyme Pharma spend in total on board compensation for fiscal 2024?
As disclosed, Inozyme Pharma reported total board compensation of $375,067 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Douglas TrecoDEF 14A2025-04-290000950170-25-060198Section “Executive Compensation”. As printed: 2,485,392. Filing ↗machine: span 345346–345355
2Section 01, Matthew WintonDEF 14A2025-04-290000950170-25-060198Section “Executive Compensation”. As printed: 1,764,899. Filing ↗machine: r6 · c22 · span 377932–377941
3Section 01, Sanjay SubramanianDEF 14A2025-04-290000950170-25-060198Section “Executive Compensation”. As printed: 1,703,737. Filing ↗machine: r4 · c22 · span 361577–361586
4Section 03, Matthew Winton RSUDEF 14A2025-04-290000950170-25-060198Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r6 · c13 · span 374595–374604
5Section 03, Douglas Treco OptionDEF 14A2025-04-290000950170-25-060198Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r2 · c13 · span 341998–342007
6Section 03, Sanjay Subramanian OptionDEF 14A2025-04-290000950170-25-060198Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t4 · r4 · c13 · span 358267–358276
7Section 08, Erik HarrisDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 282,286. Filing ↗machine: span 744216–744425
8Section 08, Reinaldo DiazDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 191,325. Filing ↗machine: span 735344–735553
9Section 08, Martin EdwardsDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 185,450. Filing ↗machine: span 739841–740050
10Section 08, Lynne SullivanDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 176,950. Filing ↗machine: span 757723–757932
11Section 08, Sarah BhagatDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 171,966. Filing ↗machine: span 726384–726691
12Section 08, Edward MathersDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 170,950. Filing ↗machine: span 753226–753435
13Section 08, Robert HopfnerDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 166,950. Filing ↗machine: span 748704–748913
14Section 08, Axel BolteDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 164,093. Filing ↗machine: span 730832–731041
15Section 08, Douglas A. TrecoDEF 14A2025-04-290000950170-25-060198Section “Director Compensation”. As printed: 0. Filing ↗
16Section 02, Axel Bolte 2025-05-15Form 42025-05-200000950170-25-075148Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Axel Bolte 2025-05-15Form 42025-05-200000950170-25-075148Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Axel Bolte 2025-05-15Form 42025-05-200000950170-25-075148Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Axel Bolte 2025-05-15Form 42025-05-200000950170-25-075148Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Sanjay Subramanian 2025-06-25Form 42025-06-270000950170-25-090862Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Douglas A. Treco 2025-06-25Form 42025-06-270000950170-25-090864Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Matthew Winton 2025-06-25Form 42025-06-270000950170-25-090868Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Robert Hopfner 2025-07-01Form 42025-07-030000950170-25-094089Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Douglas A. Treco 2025-07-01Form 42025-07-030000950170-25-094091Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Axel Bolte 2025-07-01Form 42025-07-030000950170-25-094096Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Matthew Winton 2025-07-01Form 42025-07-030000950170-25-094098Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Sanjay Subramanian 2025-07-01Form 42025-07-030000950170-25-094103Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Sanjay Subramanian 2025-07-01Form 42025-07-030000950170-25-094103Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Sanjay Subramanian 2025-07-01Form 42025-07-030000950170-25-094103Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Robert Hopfner 2025-07-01Form 42025-07-030000950170-25-094089Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Douglas A. Treco 2025-07-01Form 42025-07-030000950170-25-094091Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Axel Bolte 2025-07-01Form 42025-07-030000950170-25-094096Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Sanjay Subramanian 2025-07-01Form 42025-07-030000950170-25-094103Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Douglas A. Treco 2025-07-01Form 42025-07-030000950170-25-094091Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Axel Bolte 2025-07-01Form 42025-07-030000950170-25-094096Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Matthew Winton 2025-07-01Form 42025-07-030000950170-25-094098Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Sanjay Subramanian 2025-07-01Form 42025-07-030000950170-25-094103Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Matthew Winton 2025-07-01Form 42025-07-030000950170-25-094098Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Douglas A. Treco 2025-07-01Form 42025-07-030000950170-25-094091Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Lynne Sullivan 2025-07-01Form 42025-07-030000950170-25-094093Insider equity transaction reported since the proxy statement. Filing ↗
41Section 06, 2024 voteForm 8-K2024-06-200000950170-24-075598Item 5.07 · say-on-pay result. As reported: —. Filing ↗
42Section 06, 2023 voteForm 8-K2023-06-140000950170-23-027987Item 5.07 · say-on-pay result. As reported: —. Filing ↗
43Section 06, 2022 voteForm 8-K2022-06-100000950170-22-011473Item 5.07 · say-on-pay result. As reported: —. Filing ↗
44Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
45Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
46Section 09b board cost (computed)Computed——Cash 375,067 + equity 0 + all other 0 = 375,067, summed across the director compensation table rows.machine: formula: Σ = 375,067
47Inozyme Pharma (subject), Section 10b CEO totalDEF 14A2025-04-290000950170-25-060198CEO total compensation as printed in Inozyme Pharma's own proxy. As printed: 2,485,392. Filing ↗machine: span 345346–345355

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.